January 12, 2022
A California federal judge granted preliminary approval of the $12.7 million settlement between Odonate Therapeutics Inc. and investors on Wednesday, ending a class action that accused the pharmaceutical company of misleading investors by concealing information on a trial for a chemotherapy agent in development.
August 04, 2021
Odonate Therapeutics Inc. can't shake a proposed securities class action accusing the pharmaceutical company of misleading investors by concealing information on a trial for a chemotherapy agent in development, after a California federal judge on Wednesday found that Odonate shareholders sufficiently alleged the company misled them.